EN DE
Watch AmCad BioMed Corporation for free: we tell you when fair value or trend changes.
Data-driven stock valuation

AmCad BioMed Corporation (4188) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of AmCad BioMed Corporation stock UYU 4.87, price UYU 14.25, that is 65.8% below the price, quality 35 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IE

AB AmCad BioMed Corporation logo Thin data Nov 3, 2026

AmCad BioMed Corporation

4188 · TWO
Very expensive, weak quality

Our calculation puts a fair price 66% below what the stock costs today.

Revenue last quarter 18% below a year ago.
Fair value 4.87 UYU · Strongly overvalued
Quality 35/100
Weak Growth (revenue 5y −13.8 %/yr in UYU)
Loss-making · -184.1% net margin (TTM)
Negative free cash flow
Trails peers (0/8)
Narrow moat 10/100 · thin data
Thin data
Watch AmCad BioMed Corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

37.40 UYU 9.45 UYU Fair Value 4.87 UYU May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

60‑month range 9.45 UYU – 37.40 UYU · fair‑value band 3.22 UYU – 6.09 UYU · the 14.25 UYU price screens above the 4.87 UYU fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.

Follow AmCad BioMed in your weekly email

Every Wednesday you see whether AmCad BioMed is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases.

Show moreShow less

The company's products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients.

It also developing AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA-cleared ultrasound systems; and AmCAD-UB, an AI Solution for Breast Lesion Detection.

The company was incorporated in 2008 and is based in Taipei City, Taiwan.

Stock analysis

AmCad BioMed Corporation (4188) currently trades at 14.25 UYU, while our model-based Fair Value estimate is 4.87 UYU, 66% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 80/100, which puts the data coverage at low.

Scenario range: 3.22 UYU (bear) to 6.09 UYU (bull), the price of 14.25 UYU sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

AmCad BioMed Corporation reported revenue of 30.4M TWD in FY2025 versus 85.8M TWD in FY2021, a compound −22.8%/yr. Reported net income was −55.7M TWD in FY2025.

Key figures

Market cap 1.1B UYU (≈ $26.1M) Micro · P/S ratio 36.8 · EPS (TTM) −0.8300 UYU · Return on equity −11.2% · Return on assets (EBIT) −9.2% (5-year average) · Operating margin −335% · Revenue (TTM) 28.6M UYU · Revenue growth (YoY) −17.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 23% below its 52-week high and 51% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −66%, 4188 screens richer than that median.

Fair Value models

Bear 3.22 UYU Fair Value 4.87 UYU Bull 6.09 UYU
Price 14.25 UYU · Downside -65.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 3.22 UYU 4.87 UYU 6.09 UYU 52
All 1 models by family
Asset-Based
NCAV (Graham) 3.22 UYU 4.87 UYU 6.09 UYU 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 14
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 78
Debt, balance sheet and risk of trouble
Investment 81
Does it invest with discipline instead of growing at any price?
Low Volatility 67
How calm the share price moves, does not count
Price momentum 61
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 39
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−42.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−21.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.8%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−67.0% (2020) → −289.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

4188 screens overvalued: fair value 66% below the price. Compare with Abbott Laboratories, →

Compare AmCad BioMed Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 0/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Bottom 25%
Fair Value upside −65.8% · Bottom 25%
Profitability
Return on assets −9.0% · Below median
Net margin (12 months) −184.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −17.7% · Bottom 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 2.02× · Pricier than median
P/S (12 months) 36.76× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs 4188
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs 4188
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥202.57 +10% vs 4188
DexCom, Inc DXCM $79.41 $87.35 +10% vs 4188
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs 4188
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs 4188
Siemens Healthineers AG SHL €44.66 €34.51 −23% vs 4188
Abbott Laboratories, ABT $109.93 $75.28 −32% vs 4188
Medtronic plc MDT $101.80 $65.61 −36% vs 4188
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs 4188

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AmCad BioMed Corporation: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "AmCad BioMed Corporation Fair Value". https://www.fairvalue-calculator.com/stock/4188

Frequently asked questions

Is AmCad BioMed Corporation (4188) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 4.87 UYU versus a price of 14.25 UYU, about 66% lower (overvalued).
What is the fair value of 4188?
Our model-based fair value for AmCad BioMed Corporation is 4.87 UYU (as of Nov 3, 2026), built from audited fundamentals. The current price: 14.25 UYU.
What is the quality score of 4188?
AmCad BioMed Corporation has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AmCad BioMed Corporation (4188)?
Our model-based price target is the fair value of 4.87 UYU (as of Nov 3, 2026) from 1 valuation models. Cautious scenario 3.22 UYU, optimistic scenario 6.09 UYU. It is a calculation from audited fundamentals, not an analyst target.
What is the AmCad BioMed Corporation stock forecast for 2026?
Our models put fair value at 4.87 UYU, about 66% lower versus a price of 14.25 UYU (overvalued). Cautious scenario 3.22 UYU, optimistic scenario 6.09 UYU. The calculation is refreshed regularly with new filings.
What is the revenue of AmCad BioMed Corporation (4188)?
AmCad BioMed Corporation reported trailing-twelve-month revenue of about 28.6M UYU (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of AmCad BioMed Corporation (4188)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AmCad BioMed Corporation it is 4.87 UYU per share (as of Nov 3, 2026), against a price of 14.25 UYU. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is AmCad BioMed Corporation stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 4188 trades above its calculated fair value: price 14.25 UYU, fair value 4.87 UYU, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4188?
No. The price is what the market pays today (14.25 UYU); the fair value is what the company's own numbers justify (4.87 UYU). For AmCad BioMed Corporation the two are 9.38 UYU per share apart. That gap is exactly why we show both numbers side by side.
How much is AmCad BioMed Corporation worth?
The market values AmCad BioMed Corporation at about 1.1B UYU (market capitalisation, as of Nov 3, 2026). Per share that is 14.25 UYU; our models calculate a fair value of 4.87 UYU per share.
What do the bullish and bearish scenarios say about 4188?
Our models span a range for AmCad BioMed Corporation: cautious scenario 3.22 UYU, base 4.87 UYU, optimistic 6.09 UYU per share (as of Nov 3, 2026, price 14.25 UYU). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of AmCad BioMed Corporation (4188)?
Balance-sheet figures for AmCad BioMed Corporation (as of Nov 3, 2026): return on equity −11.2%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is 4188 from its 52-week high?
AmCad BioMed Corporation trades at 14.25 UYU, about 23% below its 52-week high of 18.45 UYU and 51% above the low of 9.45 UYU (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 4.87 UYU is for.
Which stocks are comparable to AmCad BioMed Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AmCad BioMed Corporation stock attractive at the current price?
The data as of Nov 3, 2026: price 14.25 UYU, calculated fair value 4.87 UYU (−66%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4188 calculated?
We run AmCad BioMed Corporation through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 4.87 UYU builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. AmCad BioMed Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AmCad BioMed Corporation (4188)?
The closing price on Nov 6, 2026 was 14.25 UYU. Our model-based fair value is 4.87 UYU, about 66% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AmCad BioMed Corporation right now?
The price sits above even our optimistic bull case (6.09 UYU). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (3.22 UYU to 6.09 UYU) leaves room in how you read the outcome.

Key figures of AmCad BioMed Corporation

How large is the market capitalisation of AmCad BioMed Corporation (4188)?
The market capitalisation of AmCad BioMed Corporation is 1.1B UYU (≈ $26.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AmCad BioMed Corporation (4188)?
The price-to-sales ratio of AmCad BioMed Corporation is 36.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AmCad BioMed Corporation (4188)?
Earnings per share at AmCad BioMed Corporation are −0.8300 UYU. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of AmCad BioMed Corporation (4188)?
The return on equity (ROE) of AmCad BioMed Corporation is −11.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AmCad BioMed Corporation (4188)?
On an EBIT basis the return on assets of AmCad BioMed Corporation is −9.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AmCad BioMed Corporation (4188)?
The operating margin of AmCad BioMed Corporation is −335% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AmCad BioMed Corporation (4188)?
Revenue at AmCad BioMed Corporation is growing −17.7% versus a year earlier (3y avg −21.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does AmCad BioMed Corporation (4188) generate?
The free cash flow of AmCad BioMed Corporation is −47.8M UYU (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch AmCad BioMed Corporation in the live analysis

One click puts AmCad BioMed Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.